VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
IPO Year:
Exchange: NASDAQ
Website: vistagen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2025 | $0.90 | Buy → Hold | Jefferies |
| 12/17/2025 | Buy → Hold | Maxim Group | |
| 12/17/2025 | Outperform → Mkt Perform | William Blair | |
| 12/17/2025 | $1.00 | Buy → Hold | Stifel |
| 12/7/2023 | $15.00 | Hold → Buy | Jefferies |
| 8/7/2023 | $30.00 | Hold → Buy | Maxim Group |
| 7/22/2022 | Outperform → Neutral | Robert W. Baird | |
| 7/22/2022 | Buy → Hold | Jefferies | |
| 7/22/2022 | Outperform → Mkt Perform | William Blair |
Fastest customizable press release news feed in the world
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. The Company will host one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with Vistagen are encouraged to contact their Jefferies representative. About Vistagen Vistagen (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-
Dr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team," said President and Chief Executive Officer of Vistagen, Shawn Singh. "His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, wil
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time. The Company will also host one-on-one meetings during the conference. The live webcast link will be available in the Investors section of Vistagen's website, under the "Events" tab. A replay of the webcast will be archived on the Company's website following the presenta
Fasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over four months Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced preliminary positive data from the ongoing open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol fo
Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company's Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. The open label extension (OLE) portion of the PALISADE-4 study remains ongoing. "The completion of the random
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug Administration (FDA) under its U.S. Investigational New Drug (IND) application for refisolone nasal spray, the Company's non-hormonal, non-systemic product candidate in Phase 2 development for treatment of moderate to severe vasomotor symptoms (VMS) (also known as "hot flashes") due to menopause. The FDA's Study May Proceed letter enables the Company to pursue further Phase 2 clinical develo
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the following upcoming March investor conferences: Leerink Healthcare Conference Date: March 9-11, 2026 Format: One-on-one meetings Location: Miami, FL Stifel 2026 Virtual CNS Forum Date: March 17, 2026 Format: Fireside chat with President and CEO Shawn Singh and one-on-one meetings Time: 9:00 AM EDT Location: Virtual The Stifel CNS presentation will be accessible via a live webcast on the "Events" page in the Inves
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 46th Annual TD Cowen Healthcare Conference. Vistagen's President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 2, 2026, at 3:50 p.m. Eastern Time. A replay of the webcast will be archived and available following the event through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. About Vistagen Vistagen (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical com
PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Jefferies downgraded VistaGen from Buy to Hold and set a new price target of $0.90
Maxim Group downgraded VistaGen from Buy to Hold
William Blair downgraded VistaGen from Outperform to Mkt Perform
Stifel downgraded VistaGen from Buy to Hold and set a new price target of $1.00
Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00
Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00
Robert W. Baird downgraded VistaGen from Outperform to Neutral
Jefferies downgraded VistaGen from Buy to Hold
William Blair downgraded VistaGen from Outperform to Mkt Perform
Robert W. Baird initiated coverage of VistaGen with a rating of Outperform and set a new price target of $9.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
Live Leadership Updates
Dr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team," said President and Chief Executive Officer of Vistagen, Shawn Singh. "His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, wil
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po
Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors ("Board"). Following the appointment of Mr. Edick, Vistagen's Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. "We are pleased to welcome Mr. Edick to our Board of Directors," said Maggie FitzPatrick,
Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen's clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead t
Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget
Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V
Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen's Board of Directors the option to implement a future reverse stock split of the Company's issued and outstanding common stock, if necessary to maintain the Company's listing on the Nasdaq Capital Market, and Proposal No. 6 to allow for an amendment to the Company's Bylaws Vistagen Therapeutics, Inc. (NASDAQ:VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced results of voting and the partial adjournment of the Company's 2022 Annua
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer. Adler will oversee VistaGen's legal affairs and provide strategic guidance to its Executive Team and Board of Directors. "We are excited to welcome Reid to VistaGen's Executive Team," said Shawn Singh, Chief Executive Officer. "He is a visionary, trusted advisor and proven leader who brings deep legal experience across numerous domains as well a passion for helping
SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system ("CNS") disorders, today announced the appointment of Maggie FitzPatrick to its Board of Directors ("Board"), replacing Dr. Brian J. Underdown who recently retired from the Board. "Maggie is a highly-regarded public affairs strategist with extensive experience developing and executing multiple high impact customer-focused marketing communications initiatives for some of the world's la
SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ:VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system ("CNS") disorders, today announced the appointment of Mary L. Rotunno, J.D. to its Board of Directors ("Board"). "Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered nurse and transitioned to serving clients in health care law, both allowing her to pursue her steadfast commitment to helping others and advancing the futur
Live finance-specific insights
PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update. "We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational en
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 third quarter ended December 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at
PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Complete; Topline results expected by calendar year end Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update. "As we conclude the second quarter of our fiscal year, we are encouraged by our progress and remain confident in the path ahead," said Shawn Singh, President and Chief
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, November 13, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 second quarter ended September 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access a
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women's health, and cancer supportive care Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 1
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corp
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Participants may register to join the live call by following the link here to receive the dial-in numbers and
Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 202
Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. The conference call is being webcast live and a link can be found under "Events" in the Investors section of the Company's website. Participants may register for the live call link HERE to receive the dial-in numbers and uni
This live feed shows all institutional transactions in real time.
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)
SC 13G - Vistagen Therapeutics, Inc. (0001411685) (Subject)